Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.

Journal of drugs in dermatology : JDD

Volumn 3, Issue 6, 2004, Pages 614-624

  Gottlieb, Alice B ^a   Gordon, Kenneth B ^a   Lebwohl, Mark G ^a   Caro, Ivor ^a   Walicke, Patricia A ^a   Li, Nicole ^a   Leonardi, Craig L ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; EFALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 15744387890     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)